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Abstract: The procedure of using mature, fully differentiated cells and inducing them toward 
other cell types while bypassing an intermediate pluripotent state is termed direct reprogramming. 
Avoiding the pluripotent stage during cellular conversions can be achieved either through ectopic 
expression of lineage-specific factors (transdifferentiation) or a direct reprogramming process 
that involves partial reprogramming toward the pluripotent stage. Latest advances in the field 
seek to alleviate concerns that include teratoma formation or retroviral usage when it comes to 
delivering reprogramming factors to cells. They also seek to improve efficacy and efficiency of 
cellular conversion, both in vitro and in vivo. The final products of this reprogramming approach 
could be then directly implemented in regenerative and personalized medicine.
Keywords: ESCs, iPS, PiPS, reprogramming, transdifferentiation, miRNA
Changing the cell fate
The traditional view of cell differentiation initially involved the classic concept of an 
uncommitted cell differentiating into a committed tissue-specific type.1 Since then, 
however, this view has been reassessed as it has been proven that it is entirely possible 
to change a differentiated cell’s fate toward pluripotency or toward an entirely different 
cell type.1 Somatic cells can be reprogrammed into pluripotent cells using a variety of 
methods2 that include somatic cell nuclear transfer, cell fusion, culture-induced repro-
gramming using cell extracts, and direct reprogramming, the latter being the focus of 
this review. More particularly, direct reprogramming of a cell is a complex process 
that involves a wide variety of methods and reprogramming factors (Table 1), either 
alone or in combination, and whose mechanisms of action still remain unclear. Direct 
reprogramming of cells into a different state (either pluripotent or somatic) offers one 
of the most promising developments in the field of regenerative medicine, and the 
possibilities to realize this immense potential in clinical and therapeutic applications 
need to be examined in more depth.
Regenerative medicine, stem cells, and tissue 
regeneration
Pluripotent stem cells are able to differentiate into nearly all types of cells within the 
body.3 They are undifferentiated cells that can self-renew and proliferate to undifferenti-
ated cells both in vitro and in vivo as well as into mature specialized cells.4 This offers 
the significant prospect for cell-based therapies to repair tissues or organs destroyed by 
injury, degenerative disease, aging, or cancer.5–7 A number of different types of pluripotent 
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Table 1 examples of different types of cellular reprogramming 
and their corresponding reprogramming factors used for directing 
cell fate switch
Cell origin Derived  
cell type
References
Examples of reprogramming
Fibroblasts
 Oct4, Sox2, Klf4, c-MYC
 Oct4, Sox2 + valproic acid
  Oct4, Sox2, c-MYC +  
kenpaullone
  Oct4, Klf4 + CHiR99021  
(MeFs)
iPS cells  
Takahashi13 
Huangfu,80 
Lyssiotis83 
Li82
Examples of transdifferentiation and direct reprogramming
Fibroblasts
 MyoD
Muscle  
Davis34
Pancreatic (exocrine)
 Ngn3, Pdx1, Mafa
Pancreatic  
(beta cells)
 
Zhou44
Fibroblasts
 Ascl1, Brn2, Myt1l
Neurons  
vierbuchen26
Fibroblasts
 Gata4, Mef2c, Tbx5
 Gata4, Mef2c, Tbx5, Hand2
 Gata4, Mef2c, Tbx5, veGF
 Mef2c, Myocardin, and Tbx5
Cardiomyocytes  
ieda27 
Song45 
Mathison49 
Protze46
Fibroblasts
  Myocardin, miR-1,  
miR-133, GHMT
Cardiomyocytes  
Nam29
Fibroblasts
  Oct4, Sox2, Klf4, c-MYC 
(4-day partial reprogramming)
  Oct4, Sox2, Klf4, c-MYC 
(Short reprogramming)
endothelial cells  
Margariti55 
Li62
Amniotic
 ETV2, FLI1, ERG1 
endothelial cells  
Ginsberg64
Abbreviations: Ascl1, achaete-scute homolog 1; Brn2, (brain-2) also called Pouf3 
or POU class 3 homeobox 2 ;c-MYC, c-myelocytomatosis oncogene; eRG1, epilepsy-
related gene 1; eTv2, eTS translocation variant 2; FLi1, Fli-1 proto-oncogene; eTS, 
transcription factor (previous name: Friend leukemia virus integration 1); GHMT, 
Hand2 + GMT; Hand2, heart- and neural crest derivatives-expressed protein 
2; iPS, induced pluripotent stem; Klf4, Kruppel-like factor 4; Mafa, v-maf avian 
musculoaponeurotic fibrosarcoma oncogene homolog A; Mef2c, myocyte-specific 
enhancer factor 2C; MEFs, mouse embryonic fibroblasts; miR-1, microRNA-1; miR-
133, microRNA-133; MyoD, myogenic differentiation; Myt1l, myelin transcription 
factor 1-like; Ngn3, neurogenin 3; Oct4, octamer-binding protein; Pdx1, pancreatic 
and duodenal homeobox 1; Sox2, sex determining region Y-box containing gene 2; 
Tbx5, T-box transcription factor; veGF, vascular endothelial growth factor.
stem cells have been described according to their character-
istics. These include embryonic stem cells (ESCs), which are 
able to differentiate into derivatives of the three germ layers: 
endoderm, mesoderm, and ectoderm.8 Other types of stem cells 
include somatic stem cells found in differentiated tissues,9 fetal 
stem cells derived from the fetus,10 and mesenchymal stem 
cells, a type of multipotent stromal cell.11 It is important to note 
that one of the most commonly-used assays for demonstrating 
pluripotency is forming teratomas.12
The recent discovery of induced pluripotent stem 
(iPS) cells also offers a promising strategy to generate 
therapeutically-relevant numbers of patient-specific cells.13 
iPS cells are pluripotent stem cells that have been artificially 
derived from nonpluripotent differentiated somatic cells and 
share many common features with ESCs. However, some dif-
ferences were also shown to exist between them. Namely, Chin 
et al14 showed that a small set of genes is differentially and 
continuously expressed between several iPS and ESC lines. 
In contrast to this finding however, other groups reported that 
differences between the expression profiles between these cell 
types are not consistent and may be a result of different cell 
culture conditions.15 Despite these contrasting reports how-
ever, the common transcriptome pattern that arises by looking 
at these differences seems to involve iPS cells not effectively 
silencing somatic cell gene expression and/or not inducing 
ESC-specific genes to the same level as ESCs.16
The most common source of iPS cells is usually fibroblasts 
but other sources have also been reported such as hepato-
cytes and mature B cells.17 More specifically, fibroblasts can 
be reprogrammed to stable self-renewing iPS cells which 
resemble ESCs by enforced expression of a cocktail of 
transcription factors consisting of octamer-binding protein 
(Oct4), SRY-box containing gene 2 (Sox2), Kruppel-like fac-
tor 4 (Klf4), and c-myelocytomatosis oncogene (c-Myc). iPS 
cells can be generated, expanded, and then differentiated into 
various cell types such as endothelial cells (ECs), neurons, 
and cardiomyocytes for in vitro studies or, ultimately, cell 
therapy.18–20 Moreover, constructs for molecular imaging can 
also be engaged to facilitate tracking of, for example, trans-
planted ECs in vivo.21 In addition, patient-specific cells can be 
generated to study the effects of genetic or epigenetic changes 
in patients.22 Therefore, there is huge potential to employ these 
cells for personalized medicine and vascular therapy, while 
overcoming the major disadvantages of using adult cells from 
blood vessels, which may include limited proliferation capac-
ity and susceptibility to cellular senescence.23
Limitations in ESC/iPS cell 
technology
Although, the use of iPS cells to derive a desired cell type 
may overcome these difficulties, a limitation of induced 
pluripotency is the length of time it takes to first reprogram 
the cells and then subsequently direct them to the preferred 
fate. Since the protocols to generate iPS cells include a 
number of stages, the efficiency with which the final cell 
type is generated can be low. In addition, a number of 
concerns about the fidelity and safety of iPS/ESC-derived 
cells need to be addressed before these cells could be used 
 clinically.24 More particularly, several criteria must be met 
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when it comes to iPS cells to confirm their developmental 
potential; these criteria include successful differentiation 
in vitro and the expression of specific cell surface markers 
as well as teratoma formation.2 The tumor formation should 
be able to induce differentiation to all three germ layers. In 
addition, chimera formation after iPS injection into mouse 
diploid blastocysts is another necessary test. In this manner, 
iPS cells should greatly contribute toward tissue and tetra-
ploid embryo development.2
Moreover, the lack of availability of unfertilized oocytes 
from human volunteers poses a technical challenge in iso-
lation and expansion of human ESCs.2 Regardless of low 
availability and the dependency on volunteer donation, the 
technique’s efficiency is generally low.25 Taking into account 
all these limitations related to the use and generation of iPS 
cells, other ways of reprogramming cells have been consid-
ered that involve a more direct conversion between cellular 
types while avoiding the pluripotent stage and its related 
disadvantages.
Transdifferentiation
An alternative way to bypass the pluripotent ESCs/iPS 
stage is through transdifferentiation. Studies revealed that 
fibroblasts could be converted to several lineages including 
neurons,26 cardiomyocytes,27 and hepatocytes28 by ectopic 
expression of multiple lineage-specific transcription factors 
or microRNAs (miRNAs).29 Importantly, this approach had 
also been applied in vivo using a number of lineage-specific 
transcription factors.30
History of cellular reprogramming 
and transdifferentiation
The differentiated state has been the subject of multiple 
experimental procedures that goes as far back as the 1950s. 
 Previous studies have revealed that differentiation into a spe-
cific cell type can be achieved simply by activating one or a 
few relevant genes. These key genes (master genes) are usually 
the first genes activated in specialization pathways, and they 
are also needed in eliciting responses from even more genes 
during development. Indeed, in Drosophila experiments,31,32 
master gene overexpression activated genes found in other 
cell types, affecting cells and their eventual fate.32,33 Master 
genes are also found in mammals.34 Traditional approaches 
in reprogramming have included nuclear transfer, fusion, 
and transcriptional factor-based transduction. All of these 
approaches eventually revealed that the state of differentia-
tion is not unchanging; on the contrary, it is flexible, revers-
ible, and adjustable.13,33,35,36 Initial, ground breaking cloning 
experiments in frogs during the 1950s revealed that the 
nuclear transfer from blastocysts to enucleated oocytes gave 
rise to cloned organisms and delivered one of the first definite 
indications of nonpermanent gene silencing.37 A few decades 
later, in the 1980s, the first transcription factor-based repro-
gramming experiments took place. Transfection of Myogenic 
differentiation factor (MyoD), normally expressed in skeletal 
muscle, was reported to convert embryonic mouse fibroblasts 
into muscle cells by forcing the cells to express this specific 
gene.34 After this initial success, MyoD was later used in many 
more reprogramming experiments, successfully converting 
immature chondrocytes, smooth muscle cells, and retinal cells 
into muscle cells.38 However, it could not successfully convert 
other types of cells such as hepatocytes into muscle.39
Another important reprogramming factor was discovered 
in the 1990s and it was specifically related to hematopoiesis: 
globin transcription factor 1 (Gata-1) could induce avian 
monocyte precursors into erythrocytes, eosinophils, and 
megakaryocytes.40 In 2004 it was also shown that descen-
dants derived from common lymphoid progenitors could 
also be converted to descendants of common myeloid pro-
genitors. More specifically, it was shown that B cells could 
be reprogrammed into macrophages through expression of 
CCAAT-enhancer-binding protein (C/EBP) transcription fac-
tors. The gene expression pattern and functional properties 
of the reprogrammed cells were tested by infecting CD19+ 
mouse bone marrow cells with C/EBPa/humanCD4 virus 
and its corresponding control. Cells were sorted and the 
subsequent molecular and morphological analysis revealed 
the functionality of the in vitro reprogrammed macrophages.41 
C/EBP inhibits paired box protein-5 (Pax5), a transcription 
factor which can strengthen a B cell’s commitment.41,42 Once 
the Pax5 gene is deleted, B cells dedifferentiate and turn into 
common lymphoid progenitor-like cells, which can in turn be 
differentiated into T cells.43 However, this is not considered 
direct reprogramming per se, as it requires passing through 
the lymphoid progenitor cell state first.
More recently, in 2008, Zhou et al44 demonstrated that 
by overexpressing neurogenin 3, pancreatic and duodenal 
homeobox 1(Pdx1), and v-maf avian musculoaponeurotic 
fibrosarcoma oncogene homolog A (Mafa) (NPM) exocrine 
pancreas cells were converted into insulin-secreting beta cell-
like cells. This was achieved after screening more than 1,000 
transcription factors, resulting in the identification of a number 
of genes uniquely expressed in mature beta-cells. Out of these, 
nine proved to be of great importance in the development of the 
pancreas.  Ultimately, it was found that the combination of tran-
scription factors that worked in the best possible way was NPM. 
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Functionality was tested by injecting an adult mouse pancreas 
with a combination of NPM viruses (pAd-M3); 1 month later 
numerous insulin-positive cells appeared outside of islets.44
Using a similar strategy, another study27 achieved a break-
through in reprogramming mouse fibroblast cells into beating 
cardiomyocyte-like cells; it was reported that fibroblasts could 
be directly converted into cardiomyocyte-like cells through 
overexpression of cardiac-specific factors both in vivo and 
in vitro (GATA binding protein 4 [Gata-4], myocyte-specific 
enhancer factor 2C [Mef2c], and T-box 5 [Tbx5] [GMT]).27 
Reprogramming of fibroblasts into functional neuron cells was 
also reported after forced expression of achaete-scute homolog 
1 (Ascl1), transcription factor brain-2 (also called Pouf3 or 
POU class 3 homeobox 2)[Brn2], and myelin transcription 
factor 1-like (Myt1l).26 Using lentiviral vectors to infect the 
fibroblasts, the researchers initially screened for the potential 
of 19 candidate factors to induce a neuron-like phenotype, 
and eventually the combination of Ascl1, Brn2, and myelin 
transcription factor 1-like was determined to be fundamental 
in neuron conversion. More specifically, even though Ascl1 on 
its own could still induce some immature neuron-like features, 
the other two transcription factors were also essential for the 
conversion to mature functional neuron-like cells expressing 
proteins that are neuron-specific.
Since the original report on the GMT combination by Ieda 
et al,27 transdifferentiation of fibroblasts to cardiomyocyte-like 
cells in vitro has been reported by many more groups. Song 
et al screened for transcription factor combinations and showed 
that addition of the transcription factor heart- and neural crest 
derivatives-expressed protein 2 (Hand2) to the GMT factor 
mix led to in vitro reprogramming of adult mouse tail-tip and 
cardiac fibroblasts into beating cardiac-like myocytes.45 Protze 
et al46 used an alternative screening approach to evaluate triplet 
combinations of ten candidate factors using the quantitative 
polymerase chain reaction and reported induction of a variety 
of cardiac-specific genes. More specifically, the combination 
of Mef2c, myocardin, and Tbx5 was shown to upregulate a 
wider variety of cardiac genes compared to GMT.46,47 Car-
diac reprogramming has also been reported to occur in vivo: 
Song et al45, Jayawardena et al54, and Qian et al30 all used the 
fibroblast-specific protein 1 promoter;47 however, Qian et al 
additionally used periostin, a fibroblast-specific promoter, as 
a labeling system.30 On the other hand, Song et al used tran-
scription factor 21 or epicardin promoter, which is not found in 
cardiac myocytes.45,47 In support of the earlier studies on GMT, 
Inagawa et al demonstrated GMT-mediated in vivo reprogram-
ming in infarcted mouse hearts.48 In addition, Mathison et al 
reported that vascular endothelial growth factor could improve 
GMT reprogramming efficiency in rat hearts.49 In both Qian 
et al and Song et al’s experiments, infarcted hearts showcased 
significant functional recovery. Even after all of these experi-
ments, however, it is still uncertain which combination of fac-
tors demonstrates the biggest efficiency in transdifferentiating 
to cardiomyocytes, as any comparisons take place by using 
separate experimental systems and different lab conditions.47 In 
addition, subsequent studies in cardiac reprogramming raised 
questions. For instance, despite showing that GMT-mediated 
reprogramming of heart fibroblasts could produce a significant 
number of α-myosin heavy chain-green fluorescent protein 
(α-MHC-GFP)-positive cells in a short period of time,27 very 
few of the cells within that population expressed cardiac tro-
ponin T or continued spontaneous beating after a few weeks in 
culture.47 On the contrary, spontaneous cardiomyocyte beating 
was seen at higher occurrence upon differentiation of ESCs and 
iPS cells.50,51 Since then, more recent reports failed to observe 
spontaneous beating when using lentiviruses to express GMT 
in cardiac fibroblasts.52 This raises the question of whether the 
original study’s cardiomyocytes could have originated from 
either immature cardiomyocytes or cardiac progenitor cells 
in the initial heart fibroblast pool.46 This is in accordance with 
some reports of small contaminating populations of cardio-
myocytes or progenitor cells, even after sorting purification 
procedures.53 However, despite these limitations, it seems that 
GMT and other groups of cardiac-specific groups of factors can 
still push cells toward a cardiomyocyte-like cell fate.46,47,54
Limitations
Cells generated as illustrated above may demonstrate 
restricted proliferative capacity, limited cell type diversity, 
and even senescence,55 which may in turn substantially com-
promise their potential application in regenerative therapy. 
Thus, in striving toward the prospect of generating patient-
specific tissues and organs, another approach for regenerative 
medicine was developed: direct reprogramming resulting 
in a rejuvenated55 cell phenotype, which, just like transdif-
ferentiation, also avoids reaching the pluripotent stage with 
its related disadvantages.
Direct reprogramming:  
an emerging alternative strategy
The procedure of using mature, fully differentiated somatic 
cells and inducing them toward other cell types while 
bypassing an intermediate pluripotent state is termed direct 
reprogramming. Recent advances in this field have shown it 
to be one of the most promising cellular and tissue generating 
approaches in regenerative medicine. Today, one of the most 
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desired targets in cellular reprogramming is the conversion 
of committed adult cells into pluripotent ones and also the 
generation of the preferred adult cell through direct conver-
sion between cellular types.
Before proceeding to discuss “direct reprogramming” 
it should be noted that sometimes confusion occurs 
when distinguishing this specif ic type of reprogram-
ming from conventional direct reprogramming known as 
“transdifferentiation”. For example, both approaches share 
some common features, such as direct conversion from 
one cellular type to another and being patient-specific. In 
addition, both approaches avoid reaching a final pluripotent 
stage but, on the contrary, they rely on specific signals to 
help them reach the desired cellular destination. Also for 
both, such a conversion usually occurs in a short period of 
time when compared to iPS cell generation. However, the 
cellular conversion in transdifferentiation is usually the result 
of overexpression of lineage-specific factors, which pushes 
the conversion toward the cell lineage of interest. On the 
contrary, “direct reprogramming” involves the short-term 
cellular opening of pluripotent-related pathways, which 
initially drive the cell toward the pluripotent stage, before 
directing it toward a lineage-specific path.
A complex regulatory network of transcription factors 
supports expression of cell type-specific genes and suppresses 
regulators of other lineages to establish and maintain cell 
fate during development. This stability is likely the result of 
multilayer combinations of regulation, including epigenetic/
posttranslational modifications, DNA-binding transcription 
factors, transcriptional coactivators, noncoding RNAs, and 
chromatin remodeling.56,57 As already mentioned, although 
generally stable in vivo, cell fate can, under certain experi-
mental conditions, be dominantly reprogrammed by forcing 
expression of transcription factors involved in the establish-
ment and maintenance of a distinct cellular lineage.58 Recently 
however, a new paradigm of direct reprogramming strategy 
has been devised, which involves “the conversion of one 
somatic cell type to another through direct reprogramming”.55 
We have tested whether at earlier time points during repro-
gramming it is possible to direct the epigenetically activated 
cells, which are induced by the reprogramming factors, into 
lineage-specific cell types such as ECs under defined condi-
tions by skipping pluripotency.55
The main principle of this direct reprogramming approach 
is that conventional iPS cell reprogramming proceeds as a 
slow, step-wise process. In addition, generating iPS cells 
requires an extended period of enforced transcription factor 
expression (8–12 days) and a specific signaling environment. 
To this end, fibroblasts were reprogrammed with transient 
overexpression of the reprogramming factors for 4 days. 
These cells were named partial-iPS (PiPS) cells (Figure 1). 
Importantly, PiPS cells responded to different signaling 
environments (eg, growth factors/cytokines) and were able 
to direct reprogrammed cell fate decisions. Compared with 
conventional transdifferentiation, this new method has sev-
eral advantages, such as the use of a universal transcription 
factor system and the ability to generate a rejuvenated55 mul-
tipotent progenitor cell population, able to differentiate into 
specific cell types in response to a specific stimulus. Using 
this method, vascular ECs were generated (Figure 1), which 
could prove useful in regenerative medicine,59 for example, 
vascular tissue engineering.60 The generation of tissue-engi-
neered vascular grafts represents a major breakthrough with 
enormous potential and clinical applications.61 Importantly, 
when performing functionality tests, these cells did not form 
tumors when injected into immunodeficient mice since they 
had not reached a pluripotent stage. More specifically, PiPS 
cell-derived ECs were proven to be functional in angiogenesis 
(using an ischemic limb model) and in reendothelialization 
(using tissue-engineered vessels ex vivo).55 In particular, PiPS-
derived ECs were able to form vascular-like tubes in both in 
vitro and in vivo experiments in severe combined immuno-
deficiency mice.55 The ability to convert fibroblasts to ECs 
through direct reprogramming has recently been confirmed.62 
In addition, PiPS cells are able to differentiate not only toward 
ECs but also toward smooth muscle cell lineages.63 Figure 
1 shows the different routes for cellular conversion using 
reprogramming genes: a) reprogramming to iPS cells using 
four reprogramming factors followed by differentiation to a 
specific cell lineage (such as ECs), b) direct reprogramming 
to PiPS followed by differentiation to a specific cell type, and 
c) direct conversion (without differentiation) to the desired 
cell type. It must be noted that in the case of direct conver-
sion, the mechanisms are not yet fully elucidated but may 
involve specific cell lineage genes and be characterized by 
low efficiency, senescence, and unknown conversion time 
(possibly extensive), while in reprogramming methods with 
a differentiation step, the efficiency is relatively high.
In a similar manner, a previous study has reported that 
ectopic expression of the four reprogramming factors for 
a short time in tail tip fibroblasts could be employed as a 
“shortcut” to mouse cardiogenesis.29 Recently, partial direct 
reprogramming of mature amniotic cells into ECs was also 
achieved. It was specifically reported that human amniotic 
cells could be effectively reprogrammed into vascular ECs 
(reprogrammed amniotic fluid-derived cells into vascular 
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endothelial cells [rAC-VECs]), without passing through a 
pluripotent state. They specifically showed that using ETS 
transcription factors (ETV2, FLI1, and ERG1) could induce 
rAC-VECs, and transient inhibition of transforming growth 
factor-β (TGFβ) stabilized their vascular identity. Function-
ally, rAC-VECs were able to achieve in vitro tubulogenesis 
as well as form stable vasculatures in Matrigel plugs.64
Clinical applications
Despite ongoing clinical trials using regenerative therapy, 
the repair and regeneration of cells and tissues in clini-
cal application still faces many hurdles. One of the major 
obstacles is the reduced availability of suitable cells needed 
for therapeutic purposes. A key example highlighting the 
need for readily-available sources of a large number of 
desired cells can be found in the field of cardiac disease (and 
 atherosclerosis), which is a leading cause of mortality and 
morbidity  worldwide.65 Regenerative capacity is limited in 
the adult heart,66 which necessitates the urgent development 
of fast and robust new therapies. It is important to note that 
vascular endothelium is central to cardiovascular homeosta-
sis,67 while chronic inflammation of the arterial wall, a com-
mon manifestation in atherosclerosis and an early event in 
disease processes,68 is initiated by structural alterations and EC 
 dysfunction.69 In addition, alterations in EC function facilitate 
the infiltration of inflammatory cells and regulate vascular 
smooth muscle proliferation and platelet  aggregation.70 
 Therefore, the generation of large numbers of ECs, usually 
limited in number in human patients, would be greatly ben-
eficial in combating the disease in a clinical context.
Limitations
A number of technical hurdles need to be overcome before 
generating large quantities of the desired cell type. Some 
of the most common issues include the relatively low con-
version efficiency from one type to another as well as the 
generation of a heterogeneous cell population, even after 
purification. Another factor that also needs consideration 
is the limited scalability of this cell generation system. 
Just like in transdifferentiation, the lack of a proliferative 
Lineage specific cell 
Fibroblasts
Induced pluripotent stem cells
Partially induced pluripotent
stem cells
Oct4
Klf4
Sox2
c-MYC
Direct reprogramming
Reprogramming
Direct conversion
Differentiation
Lineage specific cell 
Figure 1 Schematic diagram showing reprogramming of fibroblasts to induced pluripotent stem cells followed by differentiation, direct reprogramming of fibroblasts with 
four factors generating Partial-iPS cells, and direct conversion.
Abbreviations: c-MYC, c-myelocytomatosis oncogene; Klf4, Kruppel-like factor 4; Oct4, octamer-binding protein; Sox2, sex determining region Y-box containing gene 2.
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precursor stage compromises the cell-generating capacity of 
the system and, thus, the number of postmitotic cells is rela-
tively low and even finite.71 In addition to the above, before 
introducing direct reprogramming in clinical trials, another 
limitation that needs to be considered is that the introduction 
of viruses into human subjects is generally undesirable; the 
mechanisms of viral action in humans remain unclear and 
such usage could introduce unpredictable factors that could 
lead to infections or even cancer.72 This substantiates the need 
to consider other means of delivering reprogramming factors, 
such as, via specially modified RNA or small molecules.73 
Last but not of least importance, certain human cell types, 
such as fibroblasts, are usually more difficult to reprogram 
compared, for example, to mouse fibroblasts.74 Therefore, 
the following variables merit great importance: the starting 
cell number, the conversion capacity of the cells, and the 
efficiency of the executed reprogramming protocol.
Alternative avenues
Combinational strategies have been used to evaluate the use 
of specific miRNAs (miR-1, miR-133, miR-208, and miR-
499) for the in vitro induction of direct cell reprogramming 
of fibroblasts to cardiomyocyte-like cells. Indeed, transient 
expression of the miRNAs directed a cell fate switch, 
while the miRNA-transfected cardiac fibroblasts showed 
spontaneous calcium oscillations and transients in response 
to  depolarization.54 When miRNAs were injected into the 
myocardium of ischemic mice in vivo, a direct conversion 
of fibroblasts to cardiomyocytes was observed.54 In addition, 
it was also reported that cardiomyocytes were generated by 
direct reprogramming of human fibroblasts using myocardin, 
miR-1, miR-133, and Hand2 plus GMT (GHMT) after several 
weeks in cell  culture. However, the efficiency of conversion to 
functional cells (as shown by calcium transient measurements 
and spontaneous contraction) was comparatively lower to that 
of mouse fibroblasts, and extended cell culture maturation 
had to be employed.29 Until recently, the usual route for the 
evaluation of reprogramming has depended on nonfunctional 
measures such as flow cytometry or expression of green 
fluorescent protein (GFP). Using calcium activity, several 
known and novel combinations of transcription factors were 
compared in mouse embryonic fibroblasts. It was found that 
the most efficient combination for generating cardiomyocyte-
like cells with cardiomyocyte marker expression, consisted 
of Hand2, NK2 homeobox 5 (Nkx2.5), GATA4, Mef2c, and 
Tbx5 (HNGMT) and was .50-fold more efficient than GMT 
alone.75 Epigenetics are also of importance when it comes to 
reprogramming. Efficiency of reprogramming was shown to 
be improved by compounds that modulate epigenetic-related 
enzymes, which include histone deacetylases, histone meth-
yltransferases, and DNA methyltransferases.76 However, it 
is difficult in this case to assess specificity in inducing key 
reprogramming factors due to the fact that further studies are 
needed to elucidate reprogramming mechanisms.
For example, it was found that BIX-01294, an inhibitor 
of the histone methyltransferase EHMT2, could enhance 
Oct4, Klf4-mediated reprogramming of neural progenitor 
cells into iPS cells, ending up with levels comparable to 
those of the Oct4/Sox2/Klf4/c-Myc-based reprogramming,77 
albeit with reduced efficiency. Histone deacetylase inhibitors 
were also reported to improve reprogramming efficiency,78,79 
while in another example, valproic acid, another histone 
deacetylase inhibitor, has been used in the reprogramming 
of human fibroblasts with Oct4 and Sox2.80 Therefore, it can 
be assumed that, apart from assisting in the reprogramming 
toward a pluripotent stage, epigenetics may also enhance the 
direct reprogramming and direct conversion from one cell 
type to the next.
Signaling pathways  
and small molecules
Signal pathways, along with their modulators, have also 
proven helpful during cellular reprogramming. For example, 
the Wnt-β-catenin signaling pathway enhanced reprogram-
ming by lessening the inhibition by T cell factor-3 on 
 pluripotency.81 In addition, a glycogen synthase kinase 3 
inhibitor, CHIR99021, which can activate Wnt signaling, 
helped in reprogramming mouse embryonic fibroblasts 
(MEFs) to iPS cells through overexpression of Oct4 and 
Klf4.82 Similarly, it also helped with reprogramming human 
keratinocytes when in combination with an inhibitor of lysine 
specific demethylase 1.82 In addition, kenpaullone, an inhibi-
tor of glycogen synthase kinase 3, was also shown to replace 
Klf4 when combined with the other three reprogramming 
factors Oct4, Sox2, and C-Myc during MEFs reprogram-
ming.83  Furthermore, TGFβ signaling is important in induc-
ing epithelial-mesenchymal transition during embryonic 
development.84 The reverse process of inhibiting TGFβ can 
thus be a central and decisive event toward pluripotency: it is 
expected that inhibitors of TGFβ signaling can facilitate this 
reversal and improve reprogramming. For example, TGFβ 
receptor inhibitors can indeed enhance reprogramming and 
even replace Sox2 in MEFs.85,86 In a similar fashion, small 
molecules inhibiting TGFβ receptors, mitogen-activated pro-
tein kinase and Rho-associated protein kinase, were found to 
both improve and fast-track the reprogramming efficiency in 
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human fibroblasts.87 In another example, forskolin and dor-
somorphin were shown to assist neurogenin 2 in efficiently 
and directly converting human lung fibroblasts into neurons 
with high purity, bypassing the proliferative progenitor state. 
When transcription  factor Sox11 was included, it helped in 
efficiently converting human skin fibroblasts derived from 
healthy and unhealthy patients to cholinergic neurons.88 It is 
also important to note that compounds that stimulate glyco-
lytic metabolism have also been reported to improve repro-
gramming – for example, fructose 2,6-bisphosphate, which 
activates the phosphofructokinase 1 enzyme in a rate-limiting 
glycolytic step, or N-oxaloylglycine and quercetin, which 
activate hypoxia inducible factor-1.89 Metabolic modulation 
of genes and pathways may, therefore, also be considered as 
an alternative means toward improving cellular reprogram-
ming. Last but not least, a promising route that may increase 
the efficiency of direct reprogramming would be hypoxic 
conditions. Previous studies have shown that hypoxia has 
enhanced reprogramming by stimulating associated growth 
factor production.90
Physical enhancement of direct 
reprogramming
Cellular reprogramming may also be improved using custom-
made biomaterials. For example, instead of using Matrigel-
coated tissue culture polystyrene, a rigid material that may 
nonspecifically absorb serum proteins, polyethylene glycol 
materials that are protein absorption-resistant can be modified 
and used in its place. It was, thus, shown that polyethylene 
glycol hydrogels improved both proliferation and reprogram-
ming efficiency, almost doubling the cardiomyocyte-like cells 
that were sarcomeric α-actinin-positive, compared to the 
original studies.91 In another study, the key, reprogramming 
gene Sox2 was overexpressed in mouse fibroblasts cultured 
in a three-dimensional-spherical manner giving rise to neuron 
progenitor-like cells in vitro, which were then able to differen-
tiate into specific neuron cell types such as neurons, astrocytes, 
and oligodendrocytes. In addition, after in vivo engraftment 
into adult rat brain, the three-dimensional cellular spheres 
differentiated into neural cells, showing that neural progenitor 
cells can be directly derived from fibroblasts using a physical 
approach devoid of exogenous transcription factors.92
Even though functional retinal pigment epithelium (RPE) 
cells can be derived from either ESCs or iPS cells, direct 
reprogramming could greatly facilitate their generation. 
Using a human RPE-specific reporter (Best1::GFP) it was 
also found that cells positive for Best1::GFP were able to 
form colonies and display characteristics of early-stage RPE 
cells. Furthermore, they acquired pigmentation after activa-
tion of retinoic acid and sonic hedgehog signal pathways.93
Summary and future directions
Several of the latest advances in regenerative cell technology 
have alleviated some of the concerns of retroviral usage by 
introducing new methodologies to deliver reprogramming 
factors to cells. Such methods include episomal plasmids,94 
excisable expression systems,95 messenger RNAs and miR-
NAs,96–99 or cell-penetrating recombinant proteins.100 Even 
though recent technical advances with iPS cell reprogram-
ming have shown much promise, it is still considered slow 
and inefficient. The technology is still a long way from being 
a highly specific and directed event. Similarly, when it comes 
to direct cellular conversion with transdifferentiation, the 
resulting limited capacity for proliferation and cell diversity 
may markedly compromise any applications in regeneration-
based therapies. Thus, it is important to consider additional 
avenues in cellular reprogramming, for example, through 
partial direct reprogramming assisted by the appropriate 
use of relevant master genes, specific small molecules, or 
even physical-based enhancements. Such alternative meth-
ods and advances could possibly address the safety issues 
associated with ESCs/iPS cells and the epigenetic changes 
occurring during cell reprogramming.101,102 This could be 
achieved by avoiding the viral vector- generated iPS cells, 
where reprogramming factors integrate into the host genome 
and may increase tumorigenicity, immunogenicity, genetic/
epigenetic abnormalities,24 or ESCs’ tumorigenic potential103 
in transplanted cells. By examining and altering the dif-
ferentiated state, new avenues may widen prospects for the 
generation of novel research tools and therapeutic resources. 
The end products of such a reprogramming practice could 
be then directly implemented in regenerative and personal-
ized medicine.
Disclosure
The authors report no conflicts of interest in this work.
References
1. Ladewig J, Koch P, Brüstle O. Leveling Waddington: the emergence of 
direct programming and the loss of cell fate hierarchies. Nat Rev Mol 
Cell Biol. 2013;14(4):225–236.
2. Patel M, Yang S. Advances in reprogramming somatic cells to induced 
pluripotent stem cells. Stem Cell Rev. 2010;6(3):367–380.
3. Boiani M, Schöler HR. Regulatory networks in embryo-derived pluri-
potent stem cells. Nat Rev Mol Cell Biol. 2005;6(11):872–884.
4. Gepstein L. Derivation and potential applications of human embryonic 
stem cells. Circ Res. 2002;91(10):866–876.
5. Nakagami H, Nakagawa N, Takeya Y, et al. Model of vasculogenesis from 
embryonic stem cells for vascular research and regenerative medicine. 
Hypertension. 2006;48(1):112–119.
Stem Cells and Cloning: Advances and Applications 2014:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
27
Direct reprogramming of adult cells
 6. Brunt KR, Weisel RD, Li RK. Stem cells and regenerative medicine – 
future perspectives. Can J Physiol Pharmacol. 2012;90(3):327–335.
 7. Atala A. Regenerative medicine strategies. J Pediatr Surg. 2012; 
47(1):17–28.
 8. Keller G. Embryonic stem cell differentiation: emergence of a new era 
in biology and medicine. Genes Dev. 2005;19(10):1129–1155.
 9. Pillai RG. Stem cells for ocular tissue engineering and regeneration. 
Curr Top Med Chem. 2011;11(13):1606–1620.
 10. Pappa KI, Anagnou NP. Novel sources of fetal stem cells: where do 
they fit on the developmental continuum? Regen Med. 2009;4(3): 
423–433.
 11. Yen BL, Yen ML, Hsu PJ, et al. Multipotent human mesenchymal 
stromal cells mediate expansion of myeloid-derived suppressor cells 
via hepatocyte growth factor/c-Met and STAT3. Stem Cell Reports. 
2013;1(2):139–151.
 12. Lengner CJ. iPS cell technology in regenerative medicine. Ann NY Acad 
Sci. 2010;1192:38–44.
 13. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from 
mouse embryonic and adult fibroblast cultures by defined factors. Cell. 
2006;126(4):663–676.
 14. Chin MH, Mason MJ, Xie W, et al. Induced pluripotent stem cells and 
embryonic stem cells are distinguished by gene expression signatures. 
Cell Stem Cell. 2009;5(1):111–123.
 15. Saric T, Hescheler J. Stem cells and nuclear reprogramming. Minim 
Invasive Ther Allied Technol. 2008;17(2):64–78.
 16. Bilic J, Izpisua Belmonte JC. Concise review: Induced pluripotent stem 
cells versus embryonic stem cells: close enough or yet too far apart? 
Stem Cells. 2012;30(1):33–41.
 17. Yu J, Thomson JA. Pluripotent stem cell lines. Genes Dev. 2008;22(15): 
1987–1997.
 18. Rufaihah AJ, Huang NF, Kim J, et al. Human induced pluripotent stem 
cell-derived endothelial cells exhibit functional heterogeneity. Am J 
Transl Res. 2013;5(1):21–35.
 19. Hu BY, Weick JP, Yu J, et al. Neural differentiation of human induced 
pluripotent stem cells follows developmental principles but with vari-
able potency. Proc Natl Acad Sci U S A. 2010;107(9):4335–4340.
 20. Zhang J, Wilson GF, Soerens AG, et al. Functional cardiomyo-
cytes derived from human induced pluripotent stem cells. Circ Res. 
2009;104(4):e30–e41.
 21. Azhdari M, Baghaban-Eslaminejad M, Baharvand H, Aghdami N. 
Therapeutic potential of human-induced pluripotent stem cell-derived 
endothelial cells in a bleomycin-induced scleroderma mouse model. 
Stem Cell Res. 2013;10(3):288–300.
 22. Juopperi TA, Song H, Ming GL. Modeling neurological diseases 
using patient-derived induced pluripotent stem cells. Future Neurol. 
2011;6(3):363–373.
 23. Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and 
aging. Cell. 2007;130(2):223–233.
 24. Okano H, Nakamura M, Yoshida K, et al. Steps toward safe cell 
therapy using induced pluripotent stem cells. Circ Res. 2013;112(3): 
523–533.
 25. Solter D. Mammalian cloning: advances and limitations. Nat Rev Genet. 
2000;1(3):199–207.
 26. Vierbuchen T, Ostermeier A, Pang ZP, Kokubu Y, Südhof TC, 
Wernig M. Direct conversion of fibroblasts to functional neurons by 
defined factors. Nature. 2010;463(7284):1035–1041.
 27. Ieda M, Fu JD, Delgado-Olguin P, et al. Direct reprogramming of 
fibroblasts into functional cardiomyocytes by defined factors. Cell. 
2010;142(3):375–386.
 28. Sekiya S, Suzuki A. Direct conversion of mouse fibroblasts to hepatocyte-
like cells by defined factors. Nature. 2011;475(7356):390–393.
 29. Nam YJ, Song K, Luo X, et al. Reprogramming of human fibroblasts 
toward a cardiac fate. Proc Natl Acad Sci U S A. 2013;110(14): 
5588–5593.
 30. Qian L, Huang Y, Spencer CI, et al. In vivo reprogramming of 
murine cardiac fibroblasts into induced cardiomyocytes. Nature. 
2012;485(7400):593–598.
 31. Gehring WJ. The master control gene for morphogenesis and evolution 
of the eye. Genes Cells. 1996;1(1):11–15.
 32. Schneuwly S, Klemenz R, Gehring WJ. Redesigning the body plan of 
Drosophila by ectopic expression of the homoeotic gene Antennapedia. 
Nature. 1987;325(6107):816–818.
 33. Yamanaka S, Blau HM. Nuclear reprogramming to a pluripotent state 
by three approaches. Nature. 2010;465(7299):704–712.
 34. Davis RL, Weintraub H, Lassar AB. Expression of a single transfected 
cDNA converts fibroblasts to myoblasts. Cell. 1987;51(6):987–1000.
 35. Gurdon JB. Adult frogs derived from the nuclei of single somatic cells. 
Dev Biol. 1962;4:256–273.
 36. Blau HM, Pavlath GK, Hardeman EC, et al. Plasticity of the differenti-
ated state. Science. 1985;230(4727):758–766.
 37. Briggs R, King TJ. Transplantation of living nuclei from blastula cells into 
enucleated frogs’ eggs. Proc Natl Acad Sci U S A. 1952;38(5):455–463.
 38. Choi J, Costa ML, Mermelstein CS, Chagas C, Holtzer S, Holtzer H. 
MyoD converts primary dermal fibroblasts, chondroblasts, smooth 
muscle, and retinal pigmented epithelial cells into striated mononu-
cleated myoblasts and multinucleated myotubes. Proc Natl Acad Sci 
U S A. 1990;87(20):7988–7992.
 39. Schäfer BW, Blakely BT, Darlington GJ, Blau HM. Effect of cell history 
on response to helix-loop-helix family of myogenic regulators. Nature. 
1990;344(6265):454–458.
 40. Kulessa H, Frampton J, Graf T. GATA-1 reprograms avian myelo-
monocytic cell lines into eosinophils, thromboblasts, and erythroblasts. 
Genes Dev. 1995;9(10):1250–1262.
 41. Xie H, Ye M, Feng R, Graf T. Stepwise reprogramming of B cells into 
macrophages. Cell. 2004;117(5):663–676.
 42. Nutt SL, Heavey B, Rolink AG, Busslinger M. Commitment to the 
B-lymphoid lineage depends on the transcription factor Pax5. Nature. 
1999;401(6753):556–562.
 43. Cobaleda C, Jochum W, Busslinger M. Conversion of mature B cells 
into T cells by dedifferentiation to uncommitted progenitors. Nature. 
2007;449(7161):473–477.
 44. Zhou Q, Brown J, Kanarek A, Rajagopal J, Melton DA. In vivo repro-
gramming of adult pancreatic exocrine cells to beta-cells. Nature. 
2008;455(7213):627–632.
 45. Song K, Nam YJ, Luo X, et al. Heart repair by reprogramming non-
myocytes with cardiac transcription factors. Nature. 2012;485(7400): 
599–604.
 46. Protze S, Khattak S, Poulet C, Lindemann D, Tanaka EM, Ravens U. 
A new approach to transcription factor screening for reprogramming of 
fibroblasts to cardiomyocyte-like cells. J Mol Cell Cardiol. 2012;53(3): 
323–332.
 47. Addis RC, Epstein JA. Induced regeneration – the progress and prom-
ise of direct reprogramming for heart repair. Nat Med. 2013;19(7): 
829–836.
 48. Inagawa K, Miyamoto K, Yamakawa H, et al. Induction of cardiomyo-
cyte-like cells in infarct hearts by gene transfer of Gata4, Mef2c, and 
Tbx5. Circ Res. 2012;111(9):1147–1156.
 49. Mathison M, Gersch RP, Nasser A, et al. In vivo cardiac cellular repro-
gramming efficacy is enhanced by angiogenic preconditioning of the 
infarcted myocardium with vascular endothelial growth factor. J Am 
Heart Assoc. 2012;1(6):e005652.
 50. Mummery C, Ward-van Oostwaard D, Doevendans P, et al. 
 Differentiation of human embryonic stem cells to cardiomyocytes: 
role of coculture with visceral endoderm-like cells. Circulation. 2003; 
107(21):2733–2740.
 51. Narazaki G, Uosaki H, Teranishi M, et al. Directed and systematic 
differentiation of cardiovascular cells from mouse induced pluripotent 
stem cells. Circulation. 2008;118(5):498–506.
 52. Chen JX, Krane M, Deutsch MA, et al. Inefficient reprogramming of 
fibroblasts into cardiomyocytes using Gata4, Mef2c, and Tbx5. Circ 
Res. 2012;111(1):50–55.
 53. Yi BA, Mummery CL, Chien KR. Direct cardiomyocyte reprogram-
ming: a new direction for cardiovascular regenerative medicine. Cold 
Spring Harb Perspect Med. 2013;3(9):a014050.
Stem Cells and Cloning: Advances and Applications 2014:7submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
28
Kelaini et al
 54. Jayawardena TM, Egemnazarov B, Finch EA, et al. MicroRNA-
 mediated in vitro and in vivo direct reprogramming of cardiac fibroblasts 
to cardiomyocytes. Circ Res. 2012;110(11):1465–1473.
 55. Margariti A, Winkler B, Karamariti E, et al. Direct reprogramming 
of fibroblasts into endothelial cells capable of angiogenesis and reen-
dothelialization in tissue-engineered vessels. Proc Natl Acad Sci U S A. 
2012;109(34):13793–13798.
 56. Graf T, Enver T. Forcing cells to change lineages. Nature. 2009; 
462(7273):587–594.
 57. Ho L, Crabtree GR. Chromatin remodelling during development. 
Nature. 2010;463(7280):474–484.
 58. Takahashi K, Okita K, Nakagawa M, Yamanaka S. Induction of pluri-
potent stem cells from fibroblast cultures. Nat Protoc. 2007;2(12): 
3081–3089.
 59. Cherry AB, Daley GQ. Reprogramming cellular identity for regenera-
tive medicine. Cell. 2012;148(6):1110–1122.
 60. Sheridan WS, Duffy GP, Murphy BP. Mechanical characterization of 
a customized decellularized scaffold for vascular tissue engineering. 
J Mech Behav Biomed Mater. 2012;8:58–70.
 61. Novosel EC, Kleinhans C, Kluger PJ. Vascularization is the key 
challenge in tissue engineering. Adv Drug Deliv Rev. 2011;63(4–5): 
300–311.
 62. Li J, Huang NF, Zou J, et al. Conversion of human fibroblasts to func-
tional endothelial cells by defined factors. Arterioscler Thromb Vasc 
Biol. 2013;33(6):1366–1375.
 63. Karamariti E, Margariti A, Winkler B, et al. Smooth muscle cells dif-
ferentiated from reprogrammed embryonic lung fibroblasts through 
DKK3 signaling are potent for tissue engineering of vascular grafts. 
Circ Res. 2013;112(11):1433–1443.
 64. Ginsberg M, James D, Ding BS, et al. Efficient direct reprogramming 
of mature amniotic cells into endothelial cells by ETS factors and TGFβ 
suppression. Cell. 2012;151(3):559–575.
 65. Ignarro LJ, Balestrieri ML, Napoli C. Nutrition, physical activity, 
and cardiovascular disease: an update. Cardiovasc Res. 2007;73(2): 
326–340.
 66. Rasmussen TL, Raveendran G, Zhang J, Garry DJ. Getting to 
the heart of myocardial stem cells and cell therapy. Circulation. 
2011;123(16):1771–1779.
 67. Cines DB, Pollak ES, Buck CA, et al. Endothelial cells in physiology 
and in the pathophysiology of vascular disorders. Blood. 1998;91(10): 
3527–3561.
 68. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. 
Circulation. 2004;109(23 Suppl 1):III27–III32.
 69. Weber C, Noels H. Atherosclerosis: current pathogenesis and thera-
peutic options. Nat Med. 2011;17(11):1410–1422.
 70. Wong WT, Huang NF, Botham CM, Sayed N, Cooke JP. Endothelial 
cells derived from nuclear reprogramming. Circ Res. 2012;111(10): 
1363–1375.
 71. Pawlowski M, Kotter M. Generation of neural cells by direct cellular 
reprogramming. J Transplant Stem Cell Biol. 2013;1(1):7.
 72. Butel JS. Viral carcinogenesis: revelation of molecular mechanisms and 
etiology of human disease. Carcinogenesis. 2000;21(3):405–426.
 73. Srivastava D, Ieda M. Critical factors for cardiac reprogramming. Circ 
Res. 2012;111(1):5–8.
 74. Yan X, Qin H, Qu C, Tuan RS, Shi S, Huang GT. iPS cells repro-
grammed from human mesenchymal-like stem/progenitor cells of dental 
tissue origin. Stem Cells Dev. 2010;19(4):469–480.
 75. Addis RC, Ifkovits JL, Pinto F, et al. Optimization of direct fibroblast 
reprogramming to cardiomyocytes using calcium activity as a functional 
measure of success. J Mol Cell Cardiol. 2013;60:97–106.
 76. Zhang Y, Li W, Laurent T, Ding S. Small molecules, big roles – the chem-
ical manipulation of stem cell fate and somatic cell  reprogramming. J 
Cell Sci. 2012;125(Pt 23):5609–5620.
 77. Shi Y, Desponts C, Do JT, Hahm HS, Schöler HR, Ding S. Induction 
of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 
and Klf4 with small-molecule compounds. Cell Stem Cell. 2008;3(5): 
568–574.
 78. Sun G, Fu C, Shen C, Shi Y. Histone deacetylases in neural stem 
cells and induced pluripotent stem cells. J Biomed Biotechnol. 
2011;2011:835968.
 79. Mikkelsen TS, Hanna J, Zhang X, et al. Dissecting direct reprogramming 
through integrative genomic analysis. Nature. 2008;454(7200): 49–55.
 80. Huangfu D, Osafune K, Maehr R, et al. Induction of pluripotent stem 
cells from primary human fibroblasts with only Oct4 and Sox2. Nat 
Biotechnol. 2008;26(11):1269–1275.
 81. Niwa H. Wnt: what’s needed to maintain pluripotency? Nat Cell Biol. 
2011;13(9):1024–1026.
 82. Li W, Zhou H, Abujarour R, et al. Generation of human-induced 
pluripotent stem cells in the absence of exogenous Sox2. Stem Cells. 
2009;27(12):2992–3000.
 83. Lyssiotis CA, Foreman RK, Staerk J, et al. Reprogramming of murine 
fibroblasts to induced pluripotent stem cells with chemical complemen-
tation of Klf4. Proc Natl Acad Sci U S A. 2009;106(22):8912–8917.
 84. Xie L, Law BK, Chytil AM, Brown KA, Aakre ME, Moses HL. 
 Activation of the Erk pathway is required for TGF-beta1-induced 
EMT in vitro. Neoplasia. 2004;6(5):603–610.
 85. Ichida JK, Blanchard J, Lam K, et al. A small-molecule inhibitor of 
tgf-Beta signaling replaces sox2 in reprogramming by inducing nanog. 
Cell Stem Cell. 2009;5(5):491–503.
 86. Maherali N, Hochedlinger K. Tgfbeta signal inhibition cooperates 
in the induction of iPSCs and replaces Sox2 and cMyc. Curr Biol. 
2009;19(20):1718–1723.
 87. Lin T, Ambasudhan R, Yuan X, et al. A chemical platform for improved 
induction of human iPSCs. Nat Methods. 2009;6(11):805–808.
 88. Liu ML, Zang T, Zou Y, et al. Small molecules enable neurogenin 2 
to efficiently convert human fibroblasts into cholinergic neurons. Nat 
Commun. 2013;4:2183.
 89. Zhu S, Li W, Zhou H, et al. Reprogramming of human primary 
somatic cells by OCT4 and chemical compounds. Cell Stem Cell. 
2010;7(6):651–655.
 90. Yoshida Y, Takahashi K, Okita K, Ichisaka T, Yamanaka S. Hypoxia 
enhances the generation of induced pluripotent stem cells. Cell Stem 
Cell. 2009;5(3):237–241.
 91. Smith AW, Hoyne JD, Nguyen PK, et al. Direct reprogramming of 
mouse fibroblasts to cardiomyocyte-like cells using Yamanaka factors 
on engineered poly(ethylene glycol) (PEG) hydrogels. Biomaterials. 
2013;34(28):6559–6571.
 92. Su G, Zhao Y, Wei J, et al. Direct conversion of fibroblasts into neural 
progenitor-like cells by forced growth into 3D spheres on low attach-
ment surfaces. Biomaterials. 2013;34(24):5897–5906.
 93. Zhang K, Liu GH, Yi F, et al. Direct conversion of human fibroblasts 
into retinal pigment epithelium-like cells by defined factors. Protein 
Cell. Epub June 20, 2013.
 94. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem 
cell lines derived from human somatic cells. Science. 2007;318(5858): 
1917–1920.
 95. Soldner F, Hockemeyer D, Beard C, et al. Parkinson’s disease patient-
derived induced pluripotent stem cells free of viral reprogramming 
factors. Cell. 2009;136(5):964–977.
 96. Warren L, Manos PD, Ahfeldt T, et al. Highly efficient reprogram-
ming to pluripotency and directed differentiation of human cells with 
synthetic modified mRNA. Cell Stem Cell. 2010;7(5):618–630.
 97. Yakubov E, Rechavi G, Rozenblatt S, Givol D. Reprogram-
ming of human fibroblasts to pluripotent stem cells using mRNA 
of four transcription factors. Biochem Biophys Res Commun. 
2010;394(1):189–193.
 98. Anokye-Danso F, Trivedi CM, Juhr D, et al. Highly efficient miRNA-
mediated reprogramming of mouse and human somatic cells to 
 pluripotency. Cell Stem Cell. 2011;8(4):376–388.
 99. Miyoshi N, Ishii H, Nagano H, et al. Reprogramming of mouse and 
human cells to pluripotency using mature microRNAs. Cell Stem Cell. 
2011;8(6):633–638.
 100. Zhou H, Wu S, Joo JY, et al. Generation of induced pluripotent stem cells 
using recombinant proteins. Cell Stem Cell. 2009;4(5):381–384.
Stem Cells and Cloning: Advances and Applications
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/stem-cells-and-cloning-advances-and-applications-journal
Stem Cells and Cloning: Advances and Applications is an international, 
peer-reviewed, open access journal. Areas of interest in stem cell 
research include: Embryonic stem cells; Adult stem cells; Blastocysts; 
Cordblood stem cells; Stem cell transformation and culture; Therapeutic 
cloning; Umbilical cord blood and bone marrow cells; Laboratory, 
animal and human therapeutic studies; Philosophical and ethical issues 
related to stem cell research. This journal is indexed on CAS. The 
manuscript management system is completely online and includes a 
quick and fair peer-review system. Visit http://www.dovepress.com/
testimonials.php to read real quotes from published authors.
Stem Cells and Cloning: Advances and Applications 2014:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
29
Direct reprogramming of adult cells
 101. Kim K, Doi A, Wen B, et al. Epigenetic memory in induced pluripotent 
stem cells. Nature. 2010;467(7313):285–290.
 102. Ohi Y, Qin H, Hong C, et al. Incomplete DNA methylation underlies a 
transcriptional memory of somatic cells in human iPS cells. Nat Cell 
Biol. 2011;13(5):541–549.
 103. Blum B, Benvenisty N. The tumorigenicity of human embryonic stem 
cells. Adv Cancer Res. 2008;100:133–158.
